{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:17:38Z","timestamp":1790363858928,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03444-1","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T11:01:33Z","timestamp":1711796493000},"page":"2250-2261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Potential of semen coicis in enhancing the anti-tumor effects of PD-1 inhibitor on A549 cell lines by blocking the PI3K-AKT-mTOR pathway"],"prefix":"10.1007","volume":"26","author":[{"given":"Zi-Yi","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Shen","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Feng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0979-5396","authenticated-orcid":false,"given":"Xiao-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"issue":"18","key":"3444_CR1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767\u201378. https:\/\/doi.org\/10.1056\/NEJMra1514296.","journal-title":"N Engl J Med"},{"issue":"10027","key":"3444_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7.","journal-title":"Lancet"},{"issue":"7","key":"3444_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, et al. Five-year outcomes from the randomized, Phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723\u201333. https:\/\/doi.org\/10.1200\/JCO.20.01605.","journal-title":"J Clin Oncol"},{"issue":"28","key":"3444_CR4","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518\u201327. https:\/\/doi.org\/10.1200\/JCO.19.00934.","journal-title":"J Clin Oncol"},{"issue":"06","key":"3444_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.19960\/j.cnki.issn1005-0698.2022.06.001","volume":"31","author":"L Hui","year":"2022","unstructured":"Hui L, Junyan W, Mengmeng W, Xiaoyu Z, Zheng Z, Shuyue W, et al. Meta-analysis of Kanglaite injection combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer. Chinese J Pharmacoepidemiol. 2022;31(06):363\u201370. https:\/\/doi.org\/10.19960\/j.cnki.issn1005-0698.2022.06.001.","journal-title":"Chinese J Pharmacoepidemiol"},{"issue":"05","key":"3444_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.13193\/j.issn.1673-7717.2020.05.034","volume":"38","author":"XM Gui","year":"2020","unstructured":"Gui XM, Dai L, Yuan QW, Fan XM. Effects of kanglaite injection on levels of CD+3, CD+4, NK and CD+4\/CD+8 in patients with advanced non-small cell lung cancer. Chin Arch Tradit Chin Med. 2020;38(05):147\u201350. https:\/\/doi.org\/10.13193\/j.issn.1673-7717.2020.05.034.","journal-title":"Chin Arch Tradit Chin Med"},{"key":"3444_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1758-2946-6-13.PMID:24735618;PMCID:PMC4001360","volume":"6","author":"J Ru","year":"2014","unstructured":"Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13. https:\/\/doi.org\/10.1186\/1758-2946-6-13.PMID:24735618;PMCID:PMC4001360.","journal-title":"J Cheminform"},{"issue":"W1","key":"3444_CR8","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357\u201364. https:\/\/doi.org\/10.1093\/nar\/gkz382.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3444_CR9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6.","journal-title":"Nat Commun"},{"issue":"12","key":"3444_CR10","first-page":"1455","volume":"29","author":"Wu Yan","year":"2009","unstructured":"Yan Wu, Pei P, Yujie W, Rong W, Yongfang Y. Effect of Kanglaite injection on immune function of rats with Lewis lung carcinoma. J Shanghai Jiaotong Univ (Med Sci). 2009;29(12):1455\u20138.","journal-title":"J Shanghai Jiaotong Univ (Med Sci)"},{"issue":"11","key":"3444_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.13457\/j.cnki.jncm.2020.11.026","volume":"52","author":"Xu Jun","year":"2020","unstructured":"Jun Xu, Jiansheng Li, Xinhua C, Dingchao C, Yan Li. Effect of kanglaite injection on immune function in patients with gastrointestinal carcinoma. New Chin Med. 2020;52(11):91\u20133. https:\/\/doi.org\/10.13457\/j.cnki.jncm.2020.11.026.","journal-title":"New Chin Med"},{"issue":"06","key":"3444_CR12","first-page":"523","volume":"14","author":"X Youke","year":"2016","unstructured":"Youke X, Dingping H. The effect of Kanglaite on the PD-1+and CD4+T lymphocytes in the peripheral blood of patients with advanced breast cancer. Oncol Prog. 2016;14(06):523\u20135.","journal-title":"Oncol Prog"},{"issue":"7505","key":"3444_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature13444.Epub2014Jun11.Erratumin:Nature.2016Jul28;535(7613):580.PMID:24919154;PMCID:PMC4501086","volume":"510","author":"K Ali","year":"2014","unstructured":"Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014;510(7505):407\u201311. https:\/\/doi.org\/10.1038\/nature13444.Epub2014Jun11.Erratumin:Nature.2016Jul28;535(7613):580.PMID:24919154;PMCID:PMC4501086.","journal-title":"Nature"},{"issue":"11","key":"3444_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120626.PMID:29875319;PMCID:PMC6124416","volume":"J3","author":"EL Lim","year":"2018","unstructured":"Lim EL, Cugliandolo FM, Rosner DR, Gyori D, Roychoudhuri R, Okkenhaug K. Phosphoinositide 3-kinase \u03b4 inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. JCI Insight. 2018;J3(11): e120626. https:\/\/doi.org\/10.1172\/jci.insight.120626.PMID:29875319;PMCID:PMC6124416.","journal-title":"JCI Insight"},{"issue":"7911","key":"3444_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","volume":"605","author":"S Eschweiler","year":"2022","unstructured":"Eschweiler S, Ram\u00edrez-Su\u00e1stegui C, Li Y, King E, Chudley L, Thomas J, et al. Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs. Nature. 2022;605(7911):741\u20136. https:\/\/doi.org\/10.1038\/s41586-022-04685-2. (Epub 2022 May 4 PMID: 35508656; PMCID: PMC9132770).","journal-title":"Nature"},{"issue":"6","key":"3444_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","volume":"22","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W, et al. PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 2017;22(6):1026\u201333. https:\/\/doi.org\/10.1007\/s10147-017-1161-7. (Epub 2017 Jul 26 PMID: 28748356).","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"3444_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ijc.31357","volume":"143","author":"Y Gao","year":"2018","unstructured":"Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X, Li L. IFN-\u03b3-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 2018;143(4):931\u201343. https:\/\/doi.org\/10.1002\/ijc.31357. (Epub 2018 Mar 25 PMID: 29516506).","journal-title":"Int J Cancer"},{"issue":"3","key":"3444_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41416-022-01960-x","volume":"128","author":"K Abiko","year":"2023","unstructured":"Abiko K, Hamanishi J, Matsumura N, Mandai M. Dynamic host immunity and PD-L1\/PD-1 blockade efficacy: developments after \u201cIFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.\u201d Br J Cancer. 2023;128(3):461\u20137. https:\/\/doi.org\/10.1038\/s41416-022-01960-x. (Epub 2022 Sep 6 PMID: 36068276; PMCID: PMC9938281).","journal-title":"Br J Cancer"},{"issue":"1","key":"3444_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cells11010019.PMID:35011581;PMCID:PMC8750969","volume":"11","author":"J Kim","year":"2021","unstructured":"Kim J, Jang H, Lee GJ, Hur Y, Keum J, Jo JK, et al. A novel kinase inhibitor AX-0085 Inhibits Interferon-\u03b3-mediated Induction of PD-L1 expression and promotes immune reaction to lung adenocarcinoma cells. Cells. 2021;11(1):19. https:\/\/doi.org\/10.3390\/cells11010019.PMID:35011581;PMCID:PMC8750969.","journal-title":"Cells"},{"key":"3444_CR20","doi-asserted-by":"publisher","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","volume":"9","author":"H Nishikawa","year":"2021","unstructured":"Nishikawa H, Koyama S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021;9:e002591. https:\/\/doi.org\/10.1136\/jitc-2021-002591.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"3444_CR21","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1158\/1078-0432.CCR-22-3379","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, et al. IL6 mediates suppression of T- and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res. 2023;29(7):1292\u2013304. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3379.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3444_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509-523.e6. https:\/\/doi.org\/10.1016\/j.ccell.2022.04.004.","journal-title":"Cancer Cell"},{"issue":"1","key":"3444_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/0008-5472.CAN-08-1565.PMID:19118019;PMCID:PMC2651676","volume":"69","author":"B Li","year":"2009","unstructured":"Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 2009;69(1):338\u201348. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1565.PMID:19118019;PMCID:PMC2651676.","journal-title":"Cancer Res"},{"issue":"13","key":"3444_CR24","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/0008-5472.CAN-14-2524","volume":"75","author":"F Bertrand","year":"2015","unstructured":"Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariam\u00e9 AF, Touriol C, et al. Blocking tumor necrosis factor \u03b1 enhances CD8 T-cell-dependent immunity in experimental melanoma. Cancer Res. 2015;75(13):2619\u201328. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2524. (Epub 2015 May 14 PMID: 25977337).","journal-title":"Cancer Res"},{"issue":"7420","key":"3444_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412\u20136. https:\/\/doi.org\/10.1038\/nature11538.","journal-title":"Nature"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03444-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03444-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03444-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T20:17:37Z","timestamp":1724098657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03444-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3444"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03444-1","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study met the requirements of the Declaration of Helsinki of the World Medical Association. Since this study did not require any intervention or experiment related to patients, no informed consent was required after review by the Ethics Committee of our hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}